Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2014
02/20/2014WO2014028780A2 Antifungal compounds and methods of use
02/20/2014WO2014028756A1 Deuterated baricitinib
02/20/2014WO2014028755A1 Benzazocine-ring compound inhibition of tau hyperphosphorylation
02/20/2014WO2014028704A1 Stable pharmaceutical formulation of cabazitaxel
02/20/2014WO2014028675A1 Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
02/20/2014WO2014028669A1 Novel compounds for modulation of ror-gamma activity
02/20/2014WO2014028665A1 Combination therapies for treating cancer
02/20/2014WO2014028653A1 Arsenoplatin anti-cancer agents
02/20/2014WO2014028621A1 Methods and compositions useful for improving bone and joint health
02/20/2014WO2014028610A1 Methylphenidate extended release chewable tablet
02/20/2014WO2014028607A1 Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
02/20/2014WO2014028600A2 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
02/20/2014WO2014028597A2 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
02/20/2014WO2014028595A1 Deuterated ponatinib
02/20/2014WO2014028591A2 N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
02/20/2014WO2014028589A2 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
02/20/2014WO2014028587A1 Compositions comprising chitosan-drug conjugates and methods of making and using the same
02/20/2014WO2014028585A1 Compositions for targeted anti-aging therapy
02/20/2014WO2014028566A1 Combination of pi3k inhibitor and c-met inhibitor
02/20/2014WO2014028547A1 Benzodiazepines for treating small cell lung cancer
02/20/2014WO2014028545A1 Methods of preparing tecovirimat
02/20/2014WO2014028543A1 Arry-520 for use in treating cancer in a patient with low aag
02/20/2014WO2014028509A2 Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
02/20/2014WO2014028487A1 Amine-containing lipidoids and uses thereof
02/20/2014WO2014028479A1 Quinoxaline derivatives as gpr6 modulators
02/20/2014WO2014028459A1 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
02/20/2014WO2014028422A1 Method of treating onychomycosis
02/20/2014WO2014028399A1 Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders
02/20/2014WO2014028398A2 Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
02/20/2014WO2014028397A2 Laquinimod for treatment of gaba mediated disorders
02/20/2014WO2014028387A1 Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
02/20/2014WO2014028384A1 Inhibitors of human immunodeficiency virus replication
02/20/2014WO2014028381A1 Apoptosis-inducing agents
02/20/2014WO2014028343A1 Solid forms of an antiviral compound
02/20/2014WO2014028339A1 Evaluating renal injury using hyaluronic acid
02/20/2014WO2014028334A1 Selective mmp inhibitors
02/20/2014WO2014028322A1 Modulators of the histamine h3 receptor and the treatment of disorders related thereto
02/20/2014WO2014028318A1 Thrombin inhibitors
02/20/2014WO2014028081A2 Treatment of hematological neoplasms
02/20/2014WO2014028080A1 Treatment of prostate cancer and hematologic neoplasms
02/20/2014WO2014028079A1 Treatment of prostate cancer
02/20/2014WO2014028059A1 Rac1 inhibitors for the treatment of alport glomerular disease
02/20/2014WO2014028051A1 Inhibitors of protein phosphatase-1 and uses thereof
02/20/2014WO2014028049A1 Multi - layer transdermal drug delivery system
02/20/2014WO2014028042A1 Probenecid for treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure
02/20/2014WO2014028032A1 Topical skin care composition
02/20/2014WO2014028025A1 Compositions and methods for treating myotonic dystrophy type 1
02/20/2014WO2014027996A1 Improved methods for treating cancer with reduced renal toxicity
02/20/2014WO2014027994A1 Methods for treatment of cancer using lipoplatin
02/20/2014WO2014027982A2 Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
02/20/2014WO2014027981A2 Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
02/20/2014WO2014027980A1 Oral film formulations comprising dapoxetine and tadalafil
02/20/2014WO2014027979A2 Tablet formulations comprising tadalafil and dapoxetine
02/20/2014WO2014027978A1 Chewing gum formulations comprising dapoxetine and tadalafil
02/20/2014WO2014027976A1 Topical aqueous pharmaceutical compositions of flurbiprofen and chlorhexidine
02/20/2014WO2014027975A2 Novel orally administered pharmaceutical formulations
02/20/2014WO2014027974A1 Orally disintegrating formulation of paliperidone
02/20/2014WO2014027973A1 Paliperidone oral solution
02/20/2014WO2014027885A1 Product and method for supporting uridine homeostasis
02/20/2014WO2014027882A1 Product and method for supporting uridine homeostasis
02/20/2014WO2014027865A1 Composition for preventing or treating eye diseases, containing s-allyl-l-cysteine as active ingredient, and pharmaceutical formulation containing same
02/20/2014WO2014027857A1 Composition comprising alpha-iso-cubebene or alpha-iso-cubebenol as active ingredient for preventing or treating infectious or inflammatory diseases
02/20/2014WO2014027826A1 Butenolide-based compound, preparation method therefor, and pharmaceutical composition containing same
02/20/2014WO2014027696A1 Orally administrable viridiofungin derivative having anti-hcv activity
02/20/2014WO2014027669A1 Pyrroloquinoline quinone tetraalkali salt, crystals thereof, method for manufacturing same, and composition
02/20/2014WO2014027668A1 Reelin decomposition using adamts-3
02/20/2014WO2014027658A1 INTERMEDIATE FOR SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL) CYTOSINE, INTERMEDIATE FOR SYNTHESIS OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THESE INTERMEDIATES
02/20/2014WO2014027300A1 Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk)
02/20/2014WO2014027209A1 Pyrazolyl-ureas as kinase inhibitors
02/20/2014WO2014027203A1 Inflammation imaging and therapy
02/20/2014WO2014027199A1 Fak and flt3 inhibitors
02/20/2014WO2014027163A2 Cosmetic or pharmaceutical moisturising ingredient
02/20/2014WO2014027112A1 Tris(hetero)arylpyrazoles and use thereof
02/20/2014WO2014027081A1 Trisubstituted pyrido[2,3-d]pyrimidines, methods for preparing same and therapeutic uses thereof
02/20/2014WO2014027078A1 Inhibitor compounds of phosphodiesterase type 10a
02/20/2014WO2014027056A1 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
02/20/2014WO2014027017A1 Buffer substance for the treatment of wounds
02/20/2014WO2014026997A1 2,3-benzodiazepines
02/20/2014WO2014026959A1 Methods and pharmaceutical compositions for treatment of cystic fibrosis
02/20/2014WO2014026939A1 Stable pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof
02/20/2014WO2014026882A1 Azaheterocycles as bir2 and/or bir3 inhibitors
02/20/2014WO2014026881A1 Imidazo[2,1]thiazol-3-one derivatives useful as diagnostic agents for alzheimer's disease
02/20/2014WO2014026880A1 Arylethynyl pyrimidines
02/20/2014WO2014026707A1 Anti-vaginitis compositions with improved release and adherence
02/20/2014WO2014026582A1 Tenofovir diester compound, preparation method and use thereof, and pharmaceutical composition comprising the same
02/20/2014WO2014026557A1 Use of 3-amino-1-propanesulfonic acid and derivatives thereof in manufacture of medicaments for treatment of cardiovascular and cerebrovascular diseases or neurodegenerative diseases
02/20/2014WO2014026502A1 Use of chrysalis oil for improving bioavailability of small molecule drug
02/20/2014WO2014026467A1 Bicyclic substituted pyrimidine compounds
02/20/2014WO2014026372A1 Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof
02/20/2014WO2014026341A1 Pharmaceutical composition increasing cyclic amp content and availability in vivo, and preparation method thereof
02/20/2014WO2014026330A1 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
02/20/2014WO2014026329A1 N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
02/20/2014WO2014026328A1 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
02/20/2014WO2014026327A1 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
02/20/2014WO2014026284A1 Internal structured self assembling liposomes
02/20/2014WO2014026261A1 Solid oral pharmaceutical preparation for preventing cerebrovascular and heart diseases, and tablet
02/20/2014WO2014026254A1 Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation
02/20/2014WO2014026243A1 Vegfr3 inhibitors
02/20/2014WO2014026242A1 Vegfr3 inhibitors
02/20/2014WO2014026213A1 Antiseptic composition
1 ... 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 ... 7860